NovaBridge Biosciences (NBP) Accumulated Depreciation & Amortization (2021 - 2023)

NovaBridge Biosciences (NBP) has 3 years of Accumulated Depreciation & Amortization data on file, last reported at $5.1 billion in Q4 2023.

• Accumulated Depreciation & Amortization for Q4 2023 came in at $5.1 billion, down 40.72% year-over-year; the trailing twelve-month figure through Dec 2023 was $5.1 billion (down 40.72% YoY), and the FY2023 annual result was $5.1 billion, down 42.52% from the prior year.
• Accumulated Depreciation & Amortization slipped to $5.1 billion in Q4 2023 per NBP's latest filing, from $8.5 billion in the prior quarter.
• Over five years, Accumulated Depreciation & Amortization peaked at $8.5 billion in Q4 2022 and troughed at $5.1 billion in Q4 2023.
• A 3-year average of $6.9 billion and a median of $7.1 billion in 2021 frame the typical range for Accumulated Depreciation & Amortization.
• The sharpest annual moves came in 2022 and 2023: Accumulated Depreciation & Amortization gained 19.58% in 2022, then sank 40.72% in 2023.
• A 3-year view of Accumulated Depreciation & Amortization shows it stood at $7.1 billion in 2021, then grew by 19.58% to $8.5 billion in 2022, then sank by 40.72% to $5.1 billion in 2023.
• Business Quant data shows NBP's Accumulated Depreciation & Amortization at $5.1 billion in Q4 2023, $8.5 billion in Q4 2022, and $7.1 billion in Q4 2021.